Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

RNA-based Therapeutics: an Overview and Prospectus

RNA Interference and Potential Applications

Inducible RNAi System and Its Application in Novel Therapeutics.

Advances in Therapeutic Approaches Using RNA Interference as a Gene Silencing Tool

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.

Advances of Non-specific Effects on RNAi

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Application of RNA Interference in the Treatment of Diseases

Strategies of RNA Interference in Gene Therapy of Tumor Disease

RNA and CRISPR Interferences: Past, Present, and Future Perspectives

RNAi-based drug design: considerations and future directions

Powering up the molecular therapy of RNA interference by novel nanoparticles (vol 4, pg 1051, 2016)

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

RNAi-mediated Gene Silencing in Cancer Therapy

RNA Therapeutics - Research and Clinical Advancements

Recent Advances in RNA-Targeted Cancer Therapy

Enhancing Chemotherapy by RNA Interference

Advance on RNA Interference and the Regulation of its Silencing Pathways

RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise

Progress of Research on RNA Interference and Gene Silencing